{"nctId":"NCT00141271","briefTitle":"A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression","startDateStruct":{"date":"2005-07"},"conditions":["Bipolar Disorder"],"count":536,"armGroups":[{"label":"20-40mg BID arm","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Geodon (Ziprasidone)"]},{"label":"60-80mg bid arm","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Geodon (Ziprasidone)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Geodon (Ziprasidone)","otherNames":[]},{"name":"Geodon (Ziprasidone)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects must have a primary diagnosis of Bipolar I Disorder, most recent episode depressed, with or without rapid cycling, without psychotic features, as defined in Diagnostic and Statistical Manual (of Mental Disorders) - Fourth Edition - Text Revision (DSM-IV-TR) (296.5X) and confirmed by a structured Mini International Neuropsychiatric Interview (MINI)\n\nExclusion Criteria:\n\n* Subjects with a DSM-IV TR diagnosis of schizophrenia (295.XX), schizoaffective disorder (295.70), schizophreniform disorder (295.40), delusional disorder (297.1), or psychotic disorder not otherwise specified (298.9).\n* Subjects with other DSM-IV TR Axis I or Axis II disorder (in addition to Bipolar I disorder) are ineligible if the comorbid condition is clinically unstable, requires treatment, or has been a primary focus of treatment within the 6 month period prior to screening.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score","description":"Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. MADRS is 10-item instrument measuring depression; scale 0(Normal) and 6(most abnormal). Total possible score is 0 - 60.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.07","spread":"0.62"},{"groupId":"OG001","value":"-7.66","spread":"0.73"},{"groupId":"OG002","value":"-5.75","spread":"0.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.12","spread":"0.79"},{"groupId":"OG001","value":"-10.20","spread":"0.82"},{"groupId":"OG002","value":"-9.47","spread":"0.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.61","spread":"0.88"},{"groupId":"OG001","value":"-12.93","spread":"0.85"},{"groupId":"OG002","value":"-11.37","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.54","spread":"0.88"},{"groupId":"OG001","value":"-13.87","spread":"0.91"},{"groupId":"OG002","value":"-12.49","spread":"0.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.25","spread":"0.94"},{"groupId":"OG001","value":"-14.53","spread":"0.90"},{"groupId":"OG002","value":"-12.99","spread":"0.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.81","spread":"1.02"},{"groupId":"OG001","value":"-14.77","spread":"0.97"},{"groupId":"OG002","value":"-13.25","spread":"1.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.40","spread":"0.73"},{"groupId":"OG001","value":"-12.33","spread":"0.74"},{"groupId":"OG002","value":"-10.89","spread":"0.72"}]}]}]},{"type":"SECONDARY","title":"Response Greater Than or Equal to 50 Percent Decrease From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score","description":"Participants with MADRS Total Score greater or equal to 50 percent decrease from baseline responded yes; others responded no. Endpoint is last observation carried forward (LOCF) among Week 1 - Week 6; MADRS is 10-item instrument measuring depression; scale range 0(Normal) and 6 (most abnormal). Total possible score is 0 - 60","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"121","spread":null},{"groupId":"OG002","value":"133","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"92","spread":null},{"groupId":"OG002","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"67","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"74","spread":null},{"groupId":"OG002","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"82","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Greater Than or Equal to 50 Percent Decrease From Baseline in Hamilton Depression Rating Scale (HAM-D 17) Total Score","description":"Participants with greater than or equal to 50 percent decrease from baseline in HAMD-17 total score responded yes; others responded no. Endpoint is LOCF endpoint among Week 1 - 6; Total score is first 17 items of HAM-D 25: measures range of depressive symptoms; scale 0-2 or 0-4 with higher scores being more severe. Total possible score 0 - 52.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"67","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"73","spread":null},{"groupId":"OG002","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"72","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Global Assessment of Functioning (GAF)at Endpoint, Last Observation Carried Forward (LOCF)","description":"Change is observed value at endpoint minus baseline value. Endpoint is Last Observation Carried Forward (LOCF) endpoint among Week 1 - 6; GAF is used to assess global psychological, social, \\& occupational functioning; 100=normal and 0=greatest abnormality","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.11","spread":"1.38"},{"groupId":"OG001","value":"11.72","spread":"1.37"},{"groupId":"OG002","value":"11.19","spread":"1.40"}]}]}]},{"type":"SECONDARY","title":"Remission as Measured by Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Less Than or Equal to 12","description":"Response was Yes if MADRS Total Score was less than, equal to 12, if not, response was no. Endpoint is LOCF endpoint among Week 1 through 6; MADRS is 10-item instrument measuring depression; scale range 0(Normal) and 6(most abnormal)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"126","spread":null},{"groupId":"OG002","value":"134","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"101","spread":null},{"groupId":"OG002","value":"102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"63","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"89","spread":null}]}]}]},{"type":"SECONDARY","title":"Remission as Measured by Hamilton Depression (HAM-D 17) Total Score Less Than or Equal to 7","description":"Response was yes when HAM-D 17 total score was less than or equal to 7 , if not, response was no. Endpoint is LOCF endpoint among Week 1 through Week 6. Total score is first 17 items of the HAM-D 25,which measures the range of depressive symptoms; scale 0-2 or 0-4 with higher scores being more severe. Total possible score 0 - 52.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"119","spread":null},{"groupId":"OG002","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"43","spread":null},{"groupId":"OG002","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"74","spread":null},{"groupId":"OG002","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"106","spread":null},{"groupId":"OG002","value":"106","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Hamilton Depression (HAM-D 17) Total Score","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Total score is first 17 items of the HAM-D 25, which measures the range of depressive symptoms patient currently experiencing; scale 0-2 or 0-4; 0=absent or not depressed, 2 or 4=most severe or extreme. Total possible score 0 - 52.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.56","spread":"0.82"},{"groupId":"OG001","value":"-10.58","spread":"0.81"},{"groupId":"OG002","value":"-10.13","spread":"0.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.37","spread":"1.12"},{"groupId":"OG001","value":"-12.82","spread":"1.06"},{"groupId":"OG002","value":"-11.30","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.48","spread":"0.95"},{"groupId":"OG001","value":"-11.48","spread":"0.95"},{"groupId":"OG002","value":"-10.60","spread":"0.95"}]}]}]},{"type":"SECONDARY","title":"Change in Hamilton Anxiety Rating (HAM-A)","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. HAM-A is a 14-item scale: rates intensity of psychic anxiety and somatic anxiety on a 5-point severity scale (range: 0=not present to 4=very severe). Total possible score is 0 - 56.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.54","spread":"0.74"},{"groupId":"OG001","value":"-6.46","spread":"0.74"},{"groupId":"OG002","value":"-6.79","spread":"0.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.63","spread":"0.94"},{"groupId":"OG001","value":"-7.46","spread":"0.89"},{"groupId":"OG002","value":"-6.73","spread":"0.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.40","spread":"0.81"},{"groupId":"OG001","value":"-6.75","spread":"0.81"},{"groupId":"OG002","value":"-6.82","spread":"0.82"}]}]}]},{"type":"SECONDARY","title":"Change in Total Score of Young Mania Rating Scale (YMRS)","description":"Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. YMRS: 11 item instrument with scale 0 to 4 for 7 items and 0 to 8 for 4 items; 0=normal; 4 or 8=most abnormal. Total possible score is 0 - 60.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.34"},{"groupId":"OG001","value":"0.64","spread":"0.41"},{"groupId":"OG002","value":"-0.08","spread":"0.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"0.38"},{"groupId":"OG001","value":"0.64","spread":"0.41"},{"groupId":"OG002","value":"0.51","spread":"0.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.44"},{"groupId":"OG001","value":"0.11","spread":"0.39"},{"groupId":"OG002","value":"0.05","spread":"0.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.43"},{"groupId":"OG001","value":"0.19","spread":"0.49"},{"groupId":"OG002","value":"-0.73","spread":"0.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.89","spread":"0.43"},{"groupId":"OG001","value":"-0.82","spread":"0.43"},{"groupId":"OG002","value":"-0.28","spread":"0.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.86","spread":"0.42"},{"groupId":"OG001","value":"-0.03","spread":"0.50"},{"groupId":"OG002","value":"-1.00","spread":"0.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"0.33"},{"groupId":"OG001","value":"0.12","spread":"0.36"},{"groupId":"OG002","value":"-0.26","spread":"0.32"}]}]}]},{"type":"SECONDARY","title":"Change in Assessment of Global Clinical Severity of Symptoms (CGI-S)","description":"Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. CGI-S measures severity of patient's mental illness. Scale range: 0 = not assessed, 1 = normal, 7 = among most extremely ill","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.08"},{"groupId":"OG001","value":"-0.47","spread":"0.07"},{"groupId":"OG002","value":"-0.42","spread":"0.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.84","spread":"0.09"},{"groupId":"OG001","value":"-0.82","spread":"0.09"},{"groupId":"OG002","value":"-0.75","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.90","spread":"0.11"},{"groupId":"OG001","value":"-1.15","spread":"0.10"},{"groupId":"OG002","value":"-0.93","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.14","spread":"0.11"},{"groupId":"OG001","value":"-1.23","spread":"0.11"},{"groupId":"OG002","value":"-1.14","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.33","spread":"0.11"},{"groupId":"OG001","value":"-1.35","spread":"0.12"},{"groupId":"OG002","value":"-1.23","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.38","spread":"0.12"},{"groupId":"OG001","value":"-1.38","spread":"0.12"},{"groupId":"OG002","value":"-1.35","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.02","spread":"0.09"},{"groupId":"OG001","value":"-1.07","spread":"0.09"},{"groupId":"OG002","value":"-0.97","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Change in Global Clinical Improvement of Symptoms (CGI -I)","description":"Change is observed value at each visit minus baseline value. Overall is average response of Weeks 1 - 6. CGI-I is an instrument for Global assessment of improvement in patient's condition. Scale range: 0=not assessed, 1=very much improved, 7=very much worse","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.34","spread":"0.09"},{"groupId":"OG001","value":"3.17","spread":"0.09"},{"groupId":"OG002","value":"3.38","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.86","spread":"0.11"},{"groupId":"OG001","value":"2.82","spread":"0.10"},{"groupId":"OG002","value":"3.01","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.90","spread":"0.13"},{"groupId":"OG001","value":"2.62","spread":"0.11"},{"groupId":"OG002","value":"2.83","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.54","spread":"0.11"},{"groupId":"OG001","value":"2.53","spread":"0.11"},{"groupId":"OG002","value":"2.55","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.47","spread":"0.12"},{"groupId":"OG001","value":"2.48","spread":"0.12"},{"groupId":"OG002","value":"2.59","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.49","spread":"0.13"},{"groupId":"OG001","value":"2.43","spread":"0.13"},{"groupId":"OG002","value":"2.52","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.77","spread":"0.10"},{"groupId":"OG001","value":"2.67","spread":"0.09"},{"groupId":"OG002","value":"2.81","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Change in Total Score in Hamilton Depression (HAM-D 25)","description":"Change: observed value at each visit minus baseline value. Endpoint is Last Observation Carried Forward (LOCF) endpoint among Week 1 through Week 6. HAM-D 25: measures the range of depressive symptoms experienced. 25 Items with Scale range:0-2 or 0-4; 0=absent or not depressed, 2 or 4=most severe or extreme.Total possible score is 0 - 72.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.02","spread":"0.98"},{"groupId":"OG001","value":"-12.16","spread":"0.97"},{"groupId":"OG002","value":"-12.25","spread":"0.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.59","spread":"1.32"},{"groupId":"OG001","value":"-15.08","spread":"1.25"},{"groupId":"OG002","value":"-13.74","spread":"1.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.25","spread":"1.11"},{"groupId":"OG001","value":"-13.36","spread":"1.11"},{"groupId":"OG002","value":"-12.78","spread":"1.11"}]}]}]},{"type":"SECONDARY","title":"Response as Measured by CGI-I Score Less Than or Equal to 2","description":"Response each week was yes if CGI-I score less than or equal to 2 (much or very much improved), if not, response was no; Endpoint is LOCF endpoint among Week 1 through Week 6. CGI-I is a Global assessment of improvement in patient's condition. Scale range: 0=not assessed, 1=very much improved, 7=very much worse","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"118","spread":null},{"groupId":"OG002","value":"130","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"88","spread":null},{"groupId":"OG002","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"71","spread":null},{"groupId":"OG002","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"60","spread":null},{"groupId":"OG002","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"74","spread":null},{"groupId":"OG002","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Sheehan Disability Scale (SDS) Total Score at Endpoint","description":"Observed value each visit minus baseline value. Endpoint is LOCF Week 1 through Week 6. SDS: patient rated measure of disability and impairment in 3 items: work/school, social life, family life/home responsibilities:0(no disruption)- 10(extreme disruption). Total possible is 30.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.78","spread":"1.01"},{"groupId":"OG001","value":"-5.43","spread":"1.02"},{"groupId":"OG002","value":"-6.79","spread":"1.02"}]}]}]},{"type":"SECONDARY","title":"Change in Quality of Life, Enjoyment, and Satisfaction Scale (Q-LES-Q) Total Score at Endpoint","description":"Change is observed value at each visit minus baseline value. LOCF endpoint among Week 1 through Week 6. Q-LES-Q: 16-item instrument for patients assessment of his/her quality of life; overall level of satisfaction scale 1=very poor to 5=Very good (1 item re medication can be blank). Total possible score 15 - 80","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.02"},{"groupId":"OG001","value":"0.09","spread":"0.02"},{"groupId":"OG002","value":"0.09","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Change in Bech Melancholia Score","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Bech Melancholia is the sum of Scores on 6 Items pertaining to melancholia within Hamilton Depression Rating Scale (HAM-D). Scale 0 to 4, higher scores reflecting greater severity;Total possible 0 - 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.12","spread":"0.47"},{"groupId":"OG001","value":"-5.61","spread":"0.47"},{"groupId":"OG002","value":"-5.22","spread":"0.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.91","spread":"0.65"},{"groupId":"OG001","value":"-6.93","spread":"0.62"},{"groupId":"OG002","value":"-6.23","spread":"0.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.85","spread":"0.54"},{"groupId":"OG001","value":"-6.23","spread":"0.54"},{"groupId":"OG002","value":"-5.70","spread":"0.54"}]}]}]},{"type":"SECONDARY","title":"Change in Anxiety/Somatizations Factor Total Score","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This instrument = sum of Scores on 6 Items measuring anxiety/somatization within Hamilton Depression Rating Scale (HAM-D). Scale range is 0 to 4, higher scores reflecting greater severity. Total possible 0 - 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.69","spread":"0.30"},{"groupId":"OG001","value":"-2.92","spread":"0.30"},{"groupId":"OG002","value":"-2.98","spread":"0.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.67","spread":"0.40"},{"groupId":"OG001","value":"-3.88","spread":"0.38"},{"groupId":"OG002","value":"-3.62","spread":"0.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.04","spread":"0.34"},{"groupId":"OG001","value":"-3.39","spread":"0.34"},{"groupId":"OG002","value":"-3.32","spread":"0.34"}]}]}]},{"type":"SECONDARY","title":"Change in Retardation Factor Scores","description":"Change is observed value at each visit minus baseline value. This instrument = sum of Scores of 4 items on retardation within Hamilton Depression Rating Scale (HAM-D). Scale range is 0 to 4 with higher scores reflecting greater severity. Total possible is 0 - 16.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.50","spread":"0.32"},{"groupId":"OG001","value":"-3.64","spread":"0.32"},{"groupId":"OG002","value":"-3.59","spread":"0.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.44","spread":"0.42"},{"groupId":"OG001","value":"-4.40","spread":"0.40"},{"groupId":"OG002","value":"-3.79","spread":"0.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.89","spread":"0.35"},{"groupId":"OG001","value":"-3.99","spread":"0.35"},{"groupId":"OG002","value":"-3.62","spread":"0.35"}]}]}]},{"type":"SECONDARY","title":"Change in Sleep Disturbance Factor Score","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This instrument = sum of Scores of 3 items on sleep disturbance within Hamilton Depression Rating Scale (HAM-D). Scale range 0 to 4 with higher scores reflecting greater severity. Total possible is 0 - 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.92","spread":"0.24"},{"groupId":"OG001","value":"-2.07","spread":"0.23"},{"groupId":"OG002","value":"-1.96","spread":"0.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.20","spread":"0.30"},{"groupId":"OG001","value":"-2.19","spread":"0.28"},{"groupId":"OG002","value":"-2.06","spread":"0.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.90","spread":"0.24"},{"groupId":"OG001","value":"-1.98","spread":"0.24"},{"groupId":"OG002","value":"-1.96","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Change in Verbal Memory Trial Performance Total Score at Endpoint","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This test is part of Brief Assessment of Cognition and measures recall of 15 words repeated 5 times. Range 0-75 words, higher number reflects better recall.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.31","spread":"0.97"},{"groupId":"OG001","value":"0.85","spread":"0.96"},{"groupId":"OG002","value":"1.22","spread":"1.00"}]}]}]},{"type":"SECONDARY","title":"Change in Affective Interference Test Immediate Recall List 1 Emotional Words at Endpoint","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition measuring immediate recall of 15 emotional words; higher number of words is better recall.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":"0.15"},{"groupId":"OG001","value":"-0.30","spread":"0.15"},{"groupId":"OG002","value":"-0.06","spread":"0.16"}]}]}]},{"type":"SECONDARY","title":"Change in Affective Interference Test Immediate Recall Non-Emotional Words List 1 at Endpoint","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This instrument measures immediate recall of 15 non-emotional words (List 1); higher number of words is better recall.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.15"},{"groupId":"OG001","value":"0.14","spread":"0.15"},{"groupId":"OG002","value":"-0.00","spread":"0.16"}]}]}]},{"type":"SECONDARY","title":"Change in Affective Interference Test, Immediate Recall, List 2 Emotional Words at Endpoint","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This test is in Brief Assessment of Cognition and measures immediate recall of 15 emotional words (List 2); higher number of words is better recall","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.19"},{"groupId":"OG001","value":"-0.05","spread":"0.19"},{"groupId":"OG002","value":"0.05","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Change in Affective Interference Test, Immediate Recall, List 2 Non-Emotional Words at Endpoint","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall of 15 non-emotional words (List 2); higher number of words is better recall","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.16","spread":"0.19"},{"groupId":"OG001","value":"0.07","spread":"0.19"},{"groupId":"OG002","value":"0.13","spread":"0.20"}]}]}]},{"type":"SECONDARY","title":"Change in Affective Interference Test, Immediate Recall, List 3 Emotional Words at Endpoint","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall of 15 emotional words (List 3); higher number of words is better recall","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"0.21"},{"groupId":"OG001","value":"-0.30","spread":"0.20"},{"groupId":"OG002","value":"-0.03","spread":"0.21"}]}]}]},{"type":"SECONDARY","title":"Change in Affective Interference Test, Immediate Recall, List 3 Non-Emotional Words at Endpoint","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall of 15 non-emotional words (List 3); higher number of words is better recall","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.52","spread":"0.19"},{"groupId":"OG001","value":"-0.15","spread":"0.19"},{"groupId":"OG002","value":"-0.24","spread":"0.20"}]}]}]},{"type":"SECONDARY","title":"Change in Affective Interference Test, Immediate Recall, Cued-Recall Non-Emotional Words at Endpoint","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall (Cued) of 15 non-emotional words; higher number of words is better recall","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.39","spread":"0.18"},{"groupId":"OG001","value":"-0.01","spread":"0.18"},{"groupId":"OG002","value":"-0.32","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Change in Affective Interference Test, Immediate Recall, Cued-Recall Emotional Words at Endpoint","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures immediate recall (Cued) of 15 emotional words; higher number of words is better recall","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.20"},{"groupId":"OG001","value":"-0.07","spread":"0.20"},{"groupId":"OG002","value":"0.08","spread":"0.20"}]}]}]},{"type":"SECONDARY","title":"Change in Digit Sequencing Task at Endpoint","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition in which patient sequences digits from lowest to highest. Range of number of correct responses (0-28); higher numbers show better digit sequencing and greater cognition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":"0.37"},{"groupId":"OG001","value":"0.09","spread":"0.37"},{"groupId":"OG002","value":"0.46","spread":"0.38"}]}]}]},{"type":"SECONDARY","title":"Change in Token Motor Task at Endpoint","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition in which a patient places as many of 100 tokens (2 at a time) into a container as they can within 60 seconds. The higher number of tokens placed = patient is better at motor tasks","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":"1.54"},{"groupId":"OG001","value":"-0.00","spread":"1.53"},{"groupId":"OG002","value":"2.02","spread":"1.57"}]}]}]},{"type":"SECONDARY","title":"Change in Verbal Fluency in Naming Categories at Endpoint","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition.Patients are given 60 seconds to name as many words as possible within a given category. The more words named=better cognition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"0.58"},{"groupId":"OG001","value":"-0.11","spread":"0.58"},{"groupId":"OG002","value":"-0.28","spread":"0.60"}]}]}]},{"type":"SECONDARY","title":"Change in Verbal Fluency Controlled Word Association at Endpoint","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition. Patients given 60 seconds to generate as many words as possible that begin with a given letter; better verbal fluency = more words","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.09","spread":"0.67"},{"groupId":"OG001","value":"-0.15","spread":"0.66"},{"groupId":"OG002","value":"1.54","spread":"0.69"}]}]}]},{"type":"SECONDARY","title":"Change in Symbol Coding at Endpoint","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition. For 90 seconds, Patient writes numerals 1-9 as matched to symbols. Range 0 to 110 with higher totals = better cognition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.34","spread":"1.18"},{"groupId":"OG001","value":"1.07","spread":"1.16"},{"groupId":"OG002","value":"2.66","spread":"1.21"}]}]}]},{"type":"SECONDARY","title":"Change in Tower of London Test at Endpoint","description":"Change is observed value at each visit minus baseline value. Endpoint: LOCF endpoint among Week 1 through Week 6. Brief Assessment of Cognition: subjects asked to arrange balls in 2 pictures so they are identical and give the total number of ball movements to reach this arrangment. Range: 0-22; more correct = better cognition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"0.41"},{"groupId":"OG001","value":"0.68","spread":"0.41"},{"groupId":"OG002","value":"0.91","spread":"0.43"}]}]}]},{"type":"SECONDARY","title":"Change in Affective Interference Test, Delayed Recognition, Emotional Words at Endpoint","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Test in Brief Assessment of Cognition in which the number of correct emotional words in delayed recognition is measured. Range 0-75 with higher numbers showing better cognition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":"0.22"},{"groupId":"OG001","value":"0.15","spread":"0.22"},{"groupId":"OG002","value":"0.23","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"Change in Affective Interference Test, Delayed Recognition, Emotional Words False Alarms at Endpoint","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. Test in Brief Assessment of Cognition which measures number of correct emotional word's false alarms (during delayed recognition). Higher number = better cognition","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.10"},{"groupId":"OG001","value":"0.01","spread":"0.10"},{"groupId":"OG002","value":"-0.03","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Change in Affective Interference Test, Delayed Recognition, Non-Emotional Words at Endpoint","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures number of Non-Emotional Words (Delayed Recognition); higher number of words = better cognition","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"0.23"},{"groupId":"OG001","value":"-0.24","spread":"0.23"},{"groupId":"OG002","value":"-0.02","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Change in Affective Interference Test, Delayed Recognition, Non-Emotional Words False Alarms at Endpoint","description":"Change is observed value at each visit minus baseline value. Endpoint is LOCF endpoint among Week 1 through Week 6. This is a test in Brief Assessment of Cognition which measures number of correct non-eEmotional word's false alarms(at delayed recognition). Higher number of words = greater cognition","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.15"},{"groupId":"OG001","value":"0.19","spread":"0.15"},{"groupId":"OG002","value":"0.14","spread":"0.16"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7},"commonTop":["Somnolence","Headache","Nausea","Insomnia","Sedation"]}}}